Assessment of Immediate Adverse Reactions in Children Under 2 Years of Age Following Administration of Gadoteric Acid (Gd-DOTA or Dotarem)

Trial Profile

Assessment of Immediate Adverse Reactions in Children Under 2 Years of Age Following Administration of Gadoteric Acid (Gd-DOTA or Dotarem)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Gadoterate-meglumine (Primary)
  • Indications CNS disorders; Vascular disorders
  • Focus Adverse reactions
  • Acronyms Dotarem-Study
  • Most Recent Events

    • 01 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 01 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 09 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top